Second Interim Analysis of OBI-822 Ph 3 Trial Completed and Trial Termination announced April 30, 2025
Strategic Pipeline Prioritization Announced with Focus on CB-010 and CB-011 Oncology Programs April 30, 2025
Sarah Cannon Research Institute at Colorado Blood Cancer Institute Announced as Key Clinical Trial Site for Ph 1 Trial of CER-1236 in AML April 30, 2025
Ph 1/2a CARMA study of ELC-301 continues as planned following the safety committee’s assessment of cohort 1 April 22, 2025
Clinical development of nemvaleukin to discontinue following review of data from Ph 2 ARTISTRY-6 and Ph 3 ARTISTRY-7 trials April 22, 2025
First Patient Treated in Ph 1 Trial of PHST001 for Patients with Advanced Solid Tumors April 22, 2025
Enrollment completed in Ph 2 CRDF-004 Trial of Onvansertib in 1L RAS-mutated Metastatic CRC April 22, 2025
First Patient enrolled in Ph 2 Trial of Ethanol-Free Carmustine in High-Dose Chemotherapy Prior to Transplant in Patients with HL or NHL April 22, 2025
First Patient Dosed in Ph 2 Trial of HLX22 + T-Dxd in HER2-low, HR-positive Breast cancer patients April 22, 2025
Ph 3 AdvanTIG-302 trial unlikely to meet primary endpoint; Ociperlimab (BGB-A1217) Program to be discontinued April 16, 2025
First Patient Enrolled in Ph 1b FORTRESS Trial of NG-350A in Locally Advanced Rectal Cancer Patients April 15, 2025
